Literature DB >> 30218667

Roles for Interleukin 17 and Adaptive Immunity in Pathogenesis of Colorectal Cancer.

Christopher G Hurtado1, Fengyi Wan2, Franck Housseau3, Cynthia L Sears4.   

Abstract

Sporadic colorectal cancer is one of the most common and lethal cancers worldwide. The locations and functions of immune cells in the colorectal tumor microenvironment are complex and heterogeneous. T-helper (Th)1 cell-mediated responses against established colorectal tumors are associated with better outcomes of patients (time of relapse-free or overall survival), whereas Th17 cell-mediated responses and production of interleukin 17A (IL17A) have been associated with worse outcomes of patients. Tumors that develop in mouse models of colorectal cancer are rarely invasive and differ in many ways from human colorectal tumors. However, these mice have been used to study the mechanisms by which Th17 cells and IL17A promote colorectal tumor initiation and growth, which appear to involve their direct effects on colon epithelial cells. Specific members of the colonic microbiota may promote IL17A production and IL17A-producing cell functions in the colonic mucosa to promote carcinogenesis. Increasing our understanding of the interactions between the colonic microbiota and the mucosal immune response, the roles of Th17 cells and IL17 in these interactions, and how these processes are altered during colon carcinogenesis, could lead to new strategies for preventing or treating colorectal cancer.
Copyright © 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Inflammation; Microbiota; Mouse Models Colon Carcinogenesis

Mesh:

Substances:

Year:  2018        PMID: 30218667      PMCID: PMC6441974          DOI: 10.1053/j.gastro.2018.08.056

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  37 in total

1.  Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors.

Authors:  Nicolas J Llosa; Brandon Luber; Ada J Tam; Kellie N Smith; Nicholas Siegel; Anas H Awan; Hongni Fan; Teniola Oke; JiaJia Zhang; Jada Domingue; Elizabeth L Engle; Charles A Roberts; Bjarne R Bartlett; Laveet K Aulakh; Elizabeth D Thompson; Janis M Taube; Jennifer N Durham; Cynthia L Sears; Dung T Le; Luis A Diaz; Drew M Pardoll; Hao Wang; Robert A Anders; Franck Housseau
Journal:  Clin Cancer Res       Date:  2019-05-06       Impact factor: 12.531

2.  Mismatch Repair-Proficient Colorectal Cancer: Finding the Right TiME to Respond.

Authors:  Jason A Willis; Michael J Overman; Eduardo Vilar
Journal:  Clin Cancer Res       Date:  2019-07-01       Impact factor: 12.531

3.  IL-17-CXC Chemokine Receptor 2 Axis Facilitates Breast Cancer Progression by Up-Regulating Neutrophil Recruitment.

Authors:  Lingyun Wu; Mohammad Awaji; Sugandha Saxena; Michelle L Varney; Bhawna Sharma; Rakesh K Singh
Journal:  Am J Pathol       Date:  2019-10-22       Impact factor: 4.307

4.  A chemokine/chemokine receptor signature potentially predicts clinical outcome in colorectal cancer patients.

Authors:  Andrew Mitchell; Sarrah L Hasanali; Daley S Morera; Rohitha Baskar; Xin Wang; Rahil Khan; Asif Talukder; Charles S Li; Meenakkshy Manoharan; Andre R Jordan; Jiaojiao Wang; Roni J Bollag; Nagendra Singh; Daniel Albo; Santu Ghosh; Vinata B Lokeshwar
Journal:  Cancer Biomark       Date:  2019       Impact factor: 4.388

5.  Preinvasive Colorectal Lesions of African Americans Display an Immunosuppressive Signature Compared to Caucasian Americans.

Authors:  Kristin Wallace; Georges J Nahhas; Christine Bookhout; David N Lewin; Chrystal M Paulos; Nana Nikolaishvili-Feinberg; Stephanie M Cohen; Silvia Guglietta; Ali Bakhtiari; E Ramsay Camp; Elizabeth G Hill; John A Baron; Jennifer D Wu; Alexander V Alekseyenko
Journal:  Front Oncol       Date:  2021-04-27       Impact factor: 6.244

Review 6.  From inflammatory bowel disease to colorectal cancer: what's the role of miRNAs?

Authors:  Mostafa Vaghari-Tabari; Niloufar Targhazeh; Soheila Moein; Durdi Qujeq; Forough Alemi; Maryam Majidina; Simin Younesi; Zatollah Asemi; Bahman Yousefi
Journal:  Cancer Cell Int       Date:  2022-04-11       Impact factor: 5.722

Review 7.  Gutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer.

Authors:  Carolina Mendonça Gorgulho; Anuradha Krishnamurthy; Anastasia Lanzi; Jérôme Galon; Franck Housseau; Ramon Kaneno; Michael T Lotze
Journal:  J Immunother       Date:  2021 Feb-Mar 01       Impact factor: 4.912

8.  Loss of interleukin-17 receptor D promotes chronic inflammation-associated tumorigenesis.

Authors:  Charlotte Girondel; Kim Lévesque; Marie-Josée Langlois; Sarah Pasquin; Marc K Saba-El-Leil; Nathalie Rivard; Robert Friesel; Marc J Servant; Jean-François Gauchat; Sylvie Lesage; Sylvain Meloche
Journal:  Oncogene       Date:  2020-11-11       Impact factor: 9.867

Review 9.  Angiogenesis and immune checkpoint dual blockade in combination with radiotherapy for treatment of solid cancers: opportunities and challenges.

Authors:  Lingling Zhu; Xianzhe Yu; Li Wang; Jiewei Liu; Zihan Qu; Honge Zhang; Lu Li; Jiang Chen; Qinghua Zhou
Journal:  Oncogenesis       Date:  2021-07-10       Impact factor: 7.485

Review 10.  Cruel to Be Kind: Epithelial, Microbial, and Immune Cell Interactions in Gastrointestinal Cancers.

Authors:  Shabnam Shalapour; Michael Karin
Journal:  Annu Rev Immunol       Date:  2020-02-10       Impact factor: 32.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.